Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

• Status: Recruiting
• Trial end date: 2028-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhejiang Cancer Hospital
• Treatments: Endostar protein

Criteria

Inclusion Criteria:

• Aged ≥65 years with newly pathologically confirmed NPC

• Karnofsky performance status ≥60

• Clinical stage III-IVA (Union for International Cancer Control and American Joint Committee on Cancer staging system for NPC, 8th edition)

• Adequate organ function

Exclusion Criteria:

• Cancer history

• Prior radiotherapy, cytotoxic chemotherapy, immunotherapy or target therapy

• Life-expectance within 6 months